Amylyx co-CEOs Justin Klee (L) and Josh Cohen
October 17, 2024 03:22 PM EDT
R&D

Amy­lyx presents full Phase 2 da­ta for with­drawn ALS drug in an­oth­er rare ge­net­ic dis­ease

Max Gelman

Senior Editor

Amy­lyx is try­ing to move for­ward with its ef­fort to turn its for­mer ALS drug in­to a treat­ment for oth­er con­di­tions, and da­ta re­leased Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

Benev­o­len­tAI CEO is out af­ter less than a year on the job

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

No­var­tis pays $70M up­front to li­cense Chi­nese biotech’s an­ti­tu­mor drug

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times